Patients with advanced refractory solid tumors. research hub

FIRST IN HUMAN PHASE 1 DOSE ESCALATION AND EXPANSION CLINICAL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF INTRAVENOUS AROG4-01 IN PATIENTS WITH ADVANCED SOLID TUMORS.

This study is testing a new medicine, AROG4-01, for people with advanced cancers that haven't responded to other treatments. It's the first time this medicine is being given to people. Doctors want to see if it's safe, how it moves through the body, and if it can help fight cancer.